- この都医学研セミナーは終了しました。-
演者 | Pierre Blier Departments of Psychiatry and Cellular & Molecular Medicine, University of Ottawa. Professor |
---|---|
会場 | ハイブリッド(講堂+Zoom) |
日時 | 2023年4月24日(月曜日)10:00~ |
世話人 | 井手 聡一郎 依存性物質プロジェクト 副参事研究員 |
参加自由 | 詳細は下記問合せ先まで |
お問い合わせ |
研究推進課 普及広報係 電話 03-5316-3109 |
Adjunctive medications are for most patients efficient strategies to treat a depressive episode in cases of inadequate response to a first medication. The proposed changes to the CANMAT guidelines 2016 will be presented for first-line adjunctive medications. The neuronal targets of aripiprazole and brexpiprazole will be described in order to better understand the rationale for using these two first-line adjunctive medications. Then, then the purported mechanism of action of the N-methyl-D-aspartate (NMDA) antagonists ketamine and esketamine (second-line adjunctive medications) on the glutamate system will be explained. The use and safety parameters of the use of these two rapid-acting add-ons will be explained. The impact of (es)ketamine on dopamine neurons through α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) receptors will be highlighted and a similar effect of the combination of the serotonin and norepinephrine reuptake inhibitor venlafaxine with brexpiprazole will be presented using electrophysiological experiments in the rat brain . Taken together, these preclinical and clinical results contribute to a better understanding of the antidepressant response and help guide the clinician toward more rational prescribing.